Information Provided By:
Fly News Breaks for April 9, 2019
ALRN
Apr 9, 2019 | 07:02 EDT
Canaccord analyst John Newman maintained a buy rating on Aileron Therapeutics, saying he expects ALRN-6924 preliminary Phase II data in MDM2-amplified cancers during the fourth quarter, which could be a win for the company if positive. However, the analyst lowered his price target on Aileron to $5 from $9 based on the company shifting focus from its prior lead acute myeloid leukemia and peripheral t-cell lymphoma indications to MDM2-amplified cancers.
News For ALRN From the Last 2 Days
There are no results for your query ALRN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.